Fangzhou Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fangzhou Li has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Xing-Jie Liang
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, PR China
19 shared publications Mingmei Li
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
4 shared publicationsPengli Gao
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
4 shared publicationsBozhang Xia
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing 100190 P. R. China
3 shared publicationsChenlu Huang
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, People’s Republic of China
3 shared publications- Dunwan Zhu
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China
3 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Pulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery
- 8 June 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessPulmonary surfactant camouflage lipid nanoparticles for efficient mRNA lung delivery
- 12 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114923
Boosting long-term immunity with bioengineered nanovaccines
- 12 April 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 394, 114923
Boosting long-term immunity with bioengineered nanovaccines
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
From Uptake to Therapeutic Function in Engineered Exosome Delivery Systems
Engineered exosomes are increasingly recognized as promising vehicles for precision drug delivery. Genetic display, chemical modification, physical loading, and hybrid vesicle construction have expanded their applications, while introducing additional variables to the interpretation of delivery outcomes. Because engineering can alter vesicle properties, receptor engagement, endocytic routing, intracellular trafficking, and functional readouts, tissue accumulation or cellular uptake alone is insufficient to define effective delivery. This review traces engineered exosome delivery from cellular uptake to therapeutic function, covering engineering strategies, targeting validation, endocytic routing, intracellular fate, and functional readouts. We further discuss the strengths and limitations of commonly used evaluation methods. Across biomedical applications, we emphasize that delivery evidence should be judged according to cargo type, site of action, disease model, and therapeutic mechanism. By linking engineering design, assay selection, and evidence strength, this review supports a more careful interpretation of engineered exosome delivery.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Open AccessFrom Uptake to Therapeutic Function in Engineered Exosome Delivery Systems
Engineered exosomes are increasingly recognized as promising vehicles for precision drug delivery. Genetic display, chemical modification, physical loading, and hybrid vesicle construction have expanded their applications, while introducing additional variables to the interpretation of delivery outcomes. Because engineering can alter vesicle properties, receptor engagement, endocytic routing, intracellular trafficking, and functional readouts, tissue accumulation or cellular uptake alone is insufficient to define effective delivery. This review traces engineered exosome delivery from cellular uptake to therapeutic function, covering engineering strategies, targeting validation, endocytic routing, intracellular fate, and functional readouts. We further discuss the strengths and limitations of commonly used evaluation methods. Across biomedical applications, we emphasize that delivery evidence should be judged according to cargo type, site of action, disease model, and therapeutic mechanism. By linking engineering design, assay selection, and evidence strength, this review supports a more careful interpretation of engineered exosome delivery.
- 4 December 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (47) , 27042-27065
Design and application of proton gradient-based pH-responsive nanomaterials in the tumor microenvironment
The five nanoparticles target the tumor acidic microenvironment through the mechanism of (1) ionizable groups and (2) pH-sensitive chemical bonds.
- 4 December 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (47) , 27042-27065
Design and application of proton gradient-based pH-responsive nanomaterials in the tumor microenvironment
The five nanoparticles target the tumor acidic microenvironment through the mechanism of (1) ionizable groups and (2) pH-sensitive chemical bonds.
- 16 May 2025
- Published by IOP Publishing in Nanotechnology
- Vol. 36 (22) , 222003
mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy
Chimeric antigen receptor T cells (CAR-T) immunotherapy has achieved remarkable progress in the treatment of hematological malignancies. However, it encounters challenges including complex manufacturing processes, high cost, and safety issues. Lipid nanoparticle (LNP) technology, as an advanced gene delivery platform, offers significant advancements to CAR-T therapy through its high efficiency, low immunogenicity, and safety. LNP enable in vivo production of CAR-T cells, thereby improving delivery efficiency, reducing the risks of immunogenicity and insertional mutations, simplifying the production process and reducing costs. The scalability and rapid optimization ability of LNP position them as promising candidates for CAR-T cell production. LNP technology is expected to further promote the development of CAR-T immunotherapy and provide safer and more economical treatment options. Therefore, this paper aims to provide a comprehensive and systematic review of the application of LNP in CAR-T therapy. In this review, we initially outline the fundamental design, process, and current challenges of CAR-T therapy. Subsequently, we present the characteristics of LNP, their advantages as a gene delivery vectors, and how they improve the efficacy of CAR-T therapy. Finally, we summarize the current research landscape of LNP applications in CAR-T therapy. This includes enhancing in vitro transfection of T cells, programming T cells in situ, facilitating T-cell activation, alleviating the side effects of CAR-T therapy, and combining CAR-T therapy with other immunotherapies. These advancements will aid in the design of mRNA delivery systems based on LNP, thereby promoting the development of CAR-T therapy.
- 16 May 2025
- Published by IOP Publishing in Nanotechnology
- Vol. 36 (22) , 222003
mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy
Chimeric antigen receptor T cells (CAR-T) immunotherapy has achieved remarkable progress in the treatment of hematological malignancies. However, it encounters challenges including complex manufacturing processes, high cost, and safety issues. Lipid nanoparticle (LNP) technology, as an advanced gene delivery platform, offers significant advancements to CAR-T therapy through its high efficiency, low immunogenicity, and safety. LNP enable in vivo production of CAR-T cells, thereby improving delivery efficiency, reducing the risks of immunogenicity and insertional mutations, simplifying the production process and reducing costs. The scalability and rapid optimization ability of LNP position them as promising candidates for CAR-T cell production. LNP technology is expected to further promote the development of CAR-T immunotherapy and provide safer and more economical treatment options. Therefore, this paper aims to provide a comprehensive and systematic review of the application of LNP in CAR-T therapy. In this review, we initially outline the fundamental design, process, and current challenges of CAR-T therapy. Subsequently, we present the characteristics of LNP, their advantages as a gene delivery vectors, and how they improve the efficacy of CAR-T therapy. Finally, we summarize the current research landscape of LNP applications in CAR-T therapy. This includes enhancing in vitro transfection of T cells, programming T cells in situ, facilitating T-cell activation, alleviating the side effects of CAR-T therapy, and combining CAR-T therapy with other immunotherapies. These advancements will aid in the design of mRNA delivery systems based on LNP, thereby promoting the development of CAR-T therapy.
- Open Access
- 1 April 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 46, 229-241
Compensatory effect-based oxidative stress management microneedle for psoriasis treatment
Reactive oxygen species (ROS) at elevated levels trigger oxidative DNA damage, which is a significant factor in psoriasis exacerbation. However, normal ROS levels are essential for cell signaling, cell growth regulation, differentiation, and immune responses. To address this, we developed ROS control strategies inspired by compensatory effects. DNA nanostructures with the advantage of being more stable than linear nucleic acid molecules in physiological environments were exquisitely fabricated and incorporated into microneedles (MN). These nanostructures regulate ROS levels and facilitate the delivery of IL-17A siRNA to psoriatic lesions. Our findings demonstrate that this transdermal drug delivery system effectively manages ROS levels in the psoriatic microenvironment, inhibiting pyroptosis and abnormal immune activation. Moreover, modulating ROS levels enhances the therapeutic impact of IL-17A siRNA, offering a promising in situ treatment approach for psoriasis.
- 1 April 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 46, 229-241
Open AccessCompensatory effect-based oxidative stress management microneedle for psoriasis treatment
Reactive oxygen species (ROS) at elevated levels trigger oxidative DNA damage, which is a significant factor in psoriasis exacerbation. However, normal ROS levels are essential for cell signaling, cell growth regulation, differentiation, and immune responses. To address this, we developed ROS control strategies inspired by compensatory effects. DNA nanostructures with the advantage of being more stable than linear nucleic acid molecules in physiological environments were exquisitely fabricated and incorporated into microneedles (MN). These nanostructures regulate ROS levels and facilitate the delivery of IL-17A siRNA to psoriatic lesions. Our findings demonstrate that this transdermal drug delivery system effectively manages ROS levels in the psoriatic microenvironment, inhibiting pyroptosis and abnormal immune activation. Moreover, modulating ROS levels enhances the therapeutic impact of IL-17A siRNA, offering a promising in situ treatment approach for psoriasis.
- 1 February 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 379, 993-1005
An antigen-capturing and lymph node-targeting nanoparticle for cancer immunotherapy
- 1 February 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 379, 993-1005
An antigen-capturing and lymph node-targeting nanoparticle for cancer immunotherapy
- 20 November 2024
- Published by IOP Publishing in Progress in Biomedical Engineering
- Vol. 7 (1) , 012002
The development of paliperidone nanocrystals for the treatment of schizophrenia
Schizophrenia is a complex and chronic psychiatric disorder that significantly impacts patients’ quality of life. Ranking 12th among 310 diseases and injuries that result in disability, the number of patients suffering from schizophrenia continues to rise, emphasizing the urgent need for developing effective treatments. Despite the availability of effective antipsychotic drugs, over 80% of patients taking oral antipsychotics experience relapses, primarily caused by non-adherence as the high dosing frequency is required. In this review, we discuss about schizophrenia, its incidence, pathological causes, influencing factors, and the challenges of the current medications. Specifically, we explore nanocrystal technology and its application to paliperidone, making it one of the most successful long-acting antipsychotic drugs introduced to the market. We highlight the clinical advantages of paliperidone nanocrystals, including improved adherence, efficacy, long-term outcomes, patient satisfaction, safety, and cost-effectiveness. Additionally, we address the physicochemical factors influencing the drug’s half-life, which crucially contribute to long-acting medications. Further studies on nanocrystal-based long-acting medications are crucial for enhancing their effectiveness and reliability. The successful development of paliperidone nanocrystals holds great promise as a significant approach for drug development, with potential applications for other chronic disease management.
- 20 November 2024
- Published by IOP Publishing in Progress in Biomedical Engineering
- Vol. 7 (1) , 012002
The development of paliperidone nanocrystals for the treatment of schizophrenia
Schizophrenia is a complex and chronic psychiatric disorder that significantly impacts patients’ quality of life. Ranking 12th among 310 diseases and injuries that result in disability, the number of patients suffering from schizophrenia continues to rise, emphasizing the urgent need for developing effective treatments. Despite the availability of effective antipsychotic drugs, over 80% of patients taking oral antipsychotics experience relapses, primarily caused by non-adherence as the high dosing frequency is required. In this review, we discuss about schizophrenia, its incidence, pathological causes, influencing factors, and the challenges of the current medications. Specifically, we explore nanocrystal technology and its application to paliperidone, making it one of the most successful long-acting antipsychotic drugs introduced to the market. We highlight the clinical advantages of paliperidone nanocrystals, including improved adherence, efficacy, long-term outcomes, patient satisfaction, safety, and cost-effectiveness. Additionally, we address the physicochemical factors influencing the drug’s half-life, which crucially contribute to long-acting medications. Further studies on nanocrystal-based long-acting medications are crucial for enhancing their effectiveness and reliability. The successful development of paliperidone nanocrystals holds great promise as a significant approach for drug development, with potential applications for other chronic disease management.
- Top Cited PapersOpen Access
- 23 August 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (12) , 5161-5180
Microneedles as transdermal drug delivery system for enhancing skin disease treatment
- 23 August 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (12) , 5161-5180
Top Cited PapersOpen AccessMicroneedles as transdermal drug delivery system for enhancing skin disease treatment
- 11 October 2023
- Published by H1 Connect
Faculty Opinions recommendation of In vivo metallophilic self-assembly of a light-activated anticancer drug.
This paper entitled, "In vivo metallophilic self-assembly of a light-activated anticancer drug", presents a novel approach to design self-assembling molecular drugs that can form stable supramolecular nanostructures in living mice and act as light-activated anticancer agents. The paper demonstrates that the metallophilic interaction between cyclometalated palladium complexes is strong enough to generate supramolecular nanostructures in vivo, which have a long circulation time and efficient tumour accumulation rate in a skin melanoma tumour model. The paper shows that green light activation leads to efficient tumour destruction due to the type I photodynamic effect generated by the self-assembled palladium complexes, as confirmed by in vitro and in vivo experiments. The paper provides a new strategy to use small molecules as nanodrugs directly in vivo, without the need of dedicated nanocarriers, and introduces metallophilic interactions as a new tool for nanomedicine.
- 11 October 2023
- Published by H1 Connect
Faculty Opinions recommendation of In vivo metallophilic self-assembly of a light-activated anticancer drug.
This paper entitled, "In vivo metallophilic self-assembly of a light-activated anticancer drug", presents a novel approach to design self-assembling molecular drugs that can form stable supramolecular nanostructures in living mice and act as light-activated anticancer agents. The paper demonstrates that the metallophilic interaction between cyclometalated palladium complexes is strong enough to generate supramolecular nanostructures in vivo, which have a long circulation time and efficient tumour accumulation rate in a skin melanoma tumour model. The paper shows that green light activation leads to efficient tumour destruction due to the type I photodynamic effect generated by the self-assembled palladium complexes, as confirmed by in vitro and in vivo experiments. The paper provides a new strategy to use small molecules as nanodrugs directly in vivo, without the need of dedicated nanocarriers, and introduces metallophilic interactions as a new tool for nanomedicine.